Eyedrop-based macromolecular ophthalmic drug delivery for ocular fundus disease treatment

Therapeutic antibodies are extensively used to treat fundus diseases by intravitreal injection, as eyedrop formu-lation has been rather challenging due to the presence of ocular barriers. Here, an innovative penetrating carrier was developed for antibody delivery in eyedrop formulations. We found that fluorocarbon-modified chitosan (FCS) would self-assemble with proteins to form nanocomplexes, which could effectively pass across the com-plicated ocular structure to reach the posterior eye segments in both mice and rabbits. In a choroidal melano-ma-bearing mouse model, eyedrops containing FCS/anti-PDL1 could induce stronger antitumor immune responses than those triggered by intravenous injection of anti-PDL1. Moreover, in choroidal neovasculariza-tion-bearing mouse and rabbit models, FCS/anti-VEGFA eyedrops effectively inhibited vascular proliferation, achieving comparable therapeutic responses to those observed with intravitreal injection of anti-VEGFA. Our work presents an effective delivery carrier to treat fundus diseases using eyedrop of therapeutic proteins, which may enable at-home treatment of many eye diseases with great patient compliance.

Automated summary

A novel penetrating carrier was developed for antibody delivery in eyedrop formulations, which could effectively reach the posterior eye segments. The carrier self-assembled with proteins to form nanocomplexes, allowing it to pass through the complicated ocular structure. This new delivery method has great potential for treating various eye diseases using eyedrop formulations.